"If this trial is capable of being halted -- it will be halted at the earliest possible moment and the placebo arm patients will receive leronlimab"

As of tomorrow, it will still not be halted. From my reading of this board my understanding is that the DSMC(?) will provide their guidance based on what they found upon reviewing the interim data. Their recommendation and what the Company plans to do with that recommendation is what will be discussed tomorrow.

The recommendation could be what others have posted; i.e., continue trial as is, continue with modification, halt trial and ask for EUA, etc.

So essentially, we know exactly what we knew BEFORE the scheduling of the conference call tomorrow. This stock is on helluva melodrama.